Docetaxel Versus Paclitaxel for Adjuvant Treatment of Ovarian Cancer: Case–Control Analysis of Toxicity

No abstract is available for this paper.

• Publication year

  2004

• Venue

  American Journal of Clinical Oncology

• Publication date

  2004-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.coc.0000045849.95834.6BPMID 14758127
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II

  2004cited by this paper
• Cost-minimisation analysis of three regimens of chemotherapy (docetaxel-cisplatin, paclitaxel-cisplatin, paclitaxel-carboplatin) for advanced non-small-cell lung cancer.

  2002cited by this paper
• Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.

  2001cited by this paper
• The integration of docetaxel into first-line chemotherapy for ovarian cancer

  2001cited by this paper
• Retrospective analysis of administration of a combination of docetaxel and carboplatin for advanced non-small cell lung cancer.

  2001cited by this paper
• Neurotoxicity associated with a regimen of carboplatin (AUC 5–6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies

  2001cited by this paper
• Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.

  2000cited by this paper
• Docetaxel as an Alternative to Paclitaxel after Acute Hypersensitivity Reactions

  2000cited by this paper
• Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity.

  2000cited by this paper
• Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center.

  2000cited by this paper
• 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.

  2000cited by this paper
• Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group.

  1999cited by this paper
• Taxol hypersensitivity: rapid retreatment is safe and cost effective.

  1998cited by this paper
• Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.

  1997cited by this paper
• Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview.

  1997cited by this paper
• Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

  1996cited by this paper
• Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum.

  1996cited by this paper
• Preclinical evaluation of docetaxel (Taxotere).

  1995cited by this paper
• Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer.

  1995cited by this paper
• Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination.

  1995cited by this paper
• Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.

  1994cited by this paper
• Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer.

  1994cited by this paper
• Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.

  1992cited by this paper
• Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.

  1992cited by this paper
• Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol.

  1991cited by this paper
• Relationships between the structure of taxol analogues and their antimitotic activity.

  1991cited by this paper
• © 2001 Cancer Research Campaign

  year unknowncited by this paper

• Therapeutic Challenges in the Use of Chemotherapy and Cyclin-Dependent Kinase 4/6 Inhibitors in a Patient With Charcot-Marie-Tooth Disease and Breast Cancer

  2025influential citation
• Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.

  2022cites this paper
• Where does cellular senescence belong in the pathophysiology of ovarian cancer?

  2020cites this paper
• Frontline Management of Epithelial Ovarian Cancer—Combining Clinical Expertise with Community Practice Collaboration and Cutting-Edge Research

  2020cites this paper
• Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells

  2018cites this paper
• Clinical Efficacy and Safety of Aidi Injection Plus Docetaxel-Based Chemotherapy in Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis of 36 Randomized Controlled Trials

  2018cites this paper
• Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer

  2018cites this paper
• High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer—A Phase 2 Cohort Study

  2016cites this paper
• Efficacy of taxane-based regimens in a first-line setting for recurrent and/or metastatic Chinese patients with esophageal cancer.

  2014cites this paper
• A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.

  2013cites this paper
• Weekly paclitaxel and S-1 combination chemotherapy for advanced gastric cancer

  2013cites this paper
• In search of new prognostic molecular markers in ovarian cancer

  2012cites this paper
• Clinical outcome of docetaxel in advanced or metastatic endometrial cancer.

  2012cites this paper
• Combination of docetaxel-carboplatin for adjuvant chemotherapy of epithelial ovarian, primary peritoneal and fallopian tube cancers: a meta-analysis

  2010cites this paper
• Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer

  2009cites this paper
• c-Jun-NH2-kinase-1 Inhibition Leads to Antitumor Activity in Ovarian Cancer

  2009cites this paper
• Cancer Therapy : Preclinical Clinical Cancer Research c-Jun-NH 2-kinase-1 Inhibition Leads to Antitumor Activity in Ovarian Cancer

  2009cites this paper
• Targeting Aurora Kinase with MK-0457 Inhibits Ovarian Cancer Growth

  2008cites this paper
• Phase II Study of Paclitaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer

  2008cites this paper
• Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy.

  2008cites this paper
• Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.

  2007cites this paper
• Curcumin Inhibits Tumor Growth and Angiogenesis in Ovarian Carcinoma by Targeting the Nuclear Factor-κB Pathway

  2007cites this paper
• SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer

  2006cites this paper
• Population Pharmacokinetic-Pharmacodynamic Model for Neutropenia with Patient Subgroup Identification: Comparison across Anticancer Drugs

  2006cites this paper
• Discordance of clinical symptoms and electrophysiologic findings in taxane plus platinum-induced neuropathy

  2006cites this paper
• Focal Adhesion Kinase Silencing Augments Docetaxel-Mediated Apoptosis in Ovarian Cancer Cells

  2005cites this paper
• Wirksamkeit und Toxizität der Taxane: Therapie solider Tumoren

  2005cites this paper
• Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study

  2005cites this paper
• The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study.

  2005cites this paper
• [The action and toxicity of taxanes].

  2005cites this paper
• Docetaxel in the management of ovarian cancer

  2005cites this paper
• The administration of chemotherapy in a patient with Charcot-Marie-Tooth and ovarian cancer.

  2005cites this paper
• Effects of radiotherapy and chemotherapy on sensory deficits from spinal cord damage

  2005cites this paper
• Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol.

  2004cites this paper